hepatic glucose production Inhibitors
1 drugsAbout hepatic glucose production
Hepatic glucose production is the process by which the liver generates glucose, crucial for maintaining energy balance. Dysregulation can lead to excessive glucose production, contributing to hyperglycemia and conditions like type 2 diabetes. Controlling hepatic glucose production is a key strategy in managing blood sugar levels.
Hepatic glucose production is a therapeutic target for metabolic disorders due to its role in blood sugar regulation. There is currently no genetic evidence available to support hepatic glucose production as a drug target.
XIGDUO XR (AstraZeneca) is the only FDA-approved drug that impacts hepatic glucose production, indicated for metabolic diseases. It is a small molecule approved in 2014, and no other drugs have been approved since.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 82% attractiveness score.
- White space opportunity in Albuminuria with only 4 trials.
Top hepatic glucose production Drugs
AstraZeneca is the only company with an approved drug targeting hepatic glucose production.
The market is not competitive, so new entrants may find opportunities for innovation.
hepatic glucose production Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets hepatic glucose production, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
hepatic glucose production Clinical Trials 403 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 65 | 48 | 4 | 13 | 92% |
| Phase 2 | 88 | 41 | 12 | 34 | 77% |
| Phase 3 | 113 | 67 | 3 | 41 | 96% |
| Phase 4 | 137 | 86 | 13 | 35 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved hepatic glucose production drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting hepatic glucose production. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
hepatic glucose production Drug Approval Timeline (2014 - 2014)
The first and only drug, XIGDUO XR, was approved in 2014.
The approval timeline suggests a saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 9 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 352 clinical trials targeting hepatic glucose production.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities